OM:BIOA BBiotechs
How Investors Are Reacting To BioArctic (OM:BIOA B) As Leqembi Seeks EU Monthly Dosing Approval
Eisai recently asked European Union regulators to approve a monthly intravenous maintenance dosing regimen for Leqembi in early-stage Alzheimer’s patients, following an initial 18‑month period of biweekly infusions.
This move aligns the EU treatment schedule with those in the US, UK and China, potentially improving treatment practicality and BioArctic’s royalty and milestone prospects under its partnership with Eisai.
Next, we’ll examine how the push for a monthly Leqembi dosing regimen...